Identification and Validation of Distinct Biological Phenotypes in Patients with Acute Respiratory Distress Syndrome by Cluster Analysis

Overview

Journal Thorax

Date 2017 Apr 29

PMID 28450529

Citations 155

Authors

L D Bos

L R Schouten

L A van Vught

M A Wiewel

D S Y Ong

O Cremer

A Artigas

I Martin-Loeches

A J Hoogendijk

T van der Poll

J Horn

N Juffermans

C S Calfee

M J Schultz

Affiliations

Soon will be listed here.

Abstract

Rationale: We hypothesised that patients with acute respiratory distress syndrome (ARDS) can be clustered based on concentrations of plasma biomarkers and that the thereby identified biological phenotypes are associated with mortality.

Methods: Consecutive patients with ARDS were included in this prospective observational cohort study. Cluster analysis of 20 biomarkers of inflammation, coagulation and endothelial activation provided the phenotypes in a training cohort, not taking any outcome data into account. Logistic regression with backward selection was used to select the most predictive biomarkers, and these predicted phenotypes were validated in a separate cohort. Multivariable logistic regression was used to quantify the independent association with mortality.

Results: Two phenotypes were identified in 454 patients, which we named 'uninflamed' (N=218) and 'reactive' (N=236). A selection of four biomarkers (interleukin-6, interferon gamma, angiopoietin 1/2 and plasminogen activator inhibitor-1) could be used to accurately predict the phenotype in the training cohort (area under the receiver operating characteristics curve: 0.98, 95% CI 0.97 to 0.99). Mortality rates were 15.6% and 36.4% (p<0.001) in the training cohort and 13.6% and 37.5% (p<0.001) in the validation cohort (N=207). The 'reactive phenotype' was independent from confounders associated with intensive care unit mortality (training cohort: OR 1.13, 95% CI 1.04 to 1.23; validation cohort: OR 1.18, 95% CI 1.06 to 1.31).

Conclusions: Patients with ARDS can be clustered into two biological phenotypes, with different mortality rates. Four biomarkers can be used to predict the phenotype with high accuracy. The phenotypes were very similar to those found in cohorts derived from randomised controlled trials, and these results may improve patient selection for future clinical trials targeting host response in patients with ARDS.

Citing Articles

Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.

Ma W, Tang S, Yao P, Zhou T, Niu Q, Liu P Signal Transduct Target Ther. 2025; 10(1):75.

PMID: 40050633 PMC: 11885678. DOI: 10.1038/s41392-025-02127-9.

Molecular phenotypes of critical illness confer prognostic and biological enrichment in sub-Saharan Africa: a prospective cohort study from Uganda.

Cummings M, Lutwama J, Tomoiaga A, Owor N, Lu X, Ross J Thorax. 2024; 80(3):175-179.

PMID: 39721757 PMC: 11832318. DOI: 10.1136/thorax-2024-222412.

Serum mitochondrial-encoded NADH dehydrogenase 6 and Annexin A1 as novel biomarkers for mortality prediction in critically ill patients with sepsis.

Zhou F, Chen M, Liu Y, Xia X, Zhao P Front Immunol. 2024; 15:1486322.

PMID: 39611143 PMC: 11602424. DOI: 10.3389/fimmu.2024.1486322.

Longitudinal analysis of ARDS variability and biomarker predictive power in burn patients.

Yoon J, Kym D, Cho Y, Hur J, Yoon D Sci Rep. 2024; 14(1):26376.

PMID: 39487242 PMC: 11530529. DOI: 10.1038/s41598-024-77188-x.

Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts.

Zhao Y, Yao Z, Xu S, Yao L, Yu Z J Intensive Med. 2024; 4(4):417-432.

PMID: 39310055 PMC: 11411438. DOI: 10.1016/j.jointm.2024.02.002.

References

Schulzer M, Mancini G . 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol. 1996; 25(4):704-12. DOI: 10.1093/ije/25.4.704. View

Famous K, Delucchi K, Ware L, Kangelaris K, Liu K, Thompson B . Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med. 2016; 195(3):331-338. PMC: 5328179. DOI: 10.1164/rccm.201603-0645OC. View

Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(3 Pt 1):818-24. DOI: 10.1164/ajrccm.149.3.7509706. View

Wiedemann H, Wheeler A, Bernard G, Thompson B, Hayden D, deBoisblanc B . Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006; 354(24):2564-75. DOI: 10.1056/NEJMoa062200. View

Calfee C, Matthay M . Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007; 131(3):913-920. PMC: 2789489. DOI: 10.1378/chest.06-1743. View

Durham A, Caramori G, Chung K, Adcock I . Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res. 2015; 167(1):192-203. PMC: 4728194. DOI: 10.1016/j.trsl.2015.08.004. View

Rubenfeld G, Caldwell E, Peabody E, Weaver J, Martin D, Neff M . Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353(16):1685-93. DOI: 10.1056/NEJMoa050333. View

Putensen C, Theuerkauf N, Zinserling J, Wrigge H, Pelosi P . Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med. 2009; 151(8):566-76. DOI: 10.7326/0003-4819-151-8-200910200-00011. View

Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E . Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23):2526-33. DOI: 10.1001/jama.2012.5669. View

10.

Papazian L, Forel J, Gacouin A, Penot-Ragon C, Perrin G, Loundou A . Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010; 363(12):1107-16. DOI: 10.1056/NEJMoa1005372. View

11.

Geboers D, de Beer F, Tuip-de Boer A, van der Poll T, Horn J, Cremer O . Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med. 2015; 41(7):1281-90. DOI: 10.1007/s00134-015-3924-9. View

12.

Briel M, Meade M, Mercat A, Brower R, Talmor D, Walter S . Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010; 303(9):865-73. DOI: 10.1001/jama.2010.218. View

13.

Cepkova M, Matthay M . Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med. 2006; 21(3):119-43. PMC: 2765330. DOI: 10.1177/0885066606287045. View

14.

Matute-Bello G, Downey G, Moore B, Groshong S, Matthay M, Slutsky A . An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011; 44(5):725-38. PMC: 7328339. DOI: 10.1165/rcmb.2009-0210ST. View

15.

Villar J, Ambros A, Soler J, Martinez D, Ferrando C, Solano R . Age, PaO2/FIO2, and Plateau Pressure Score: A Proposal for a Simple Outcome Score in Patients With the Acute Respiratory Distress Syndrome. Crit Care Med. 2016; 44(7):1361-9. DOI: 10.1097/CCM.0000000000001653. View

16.

Zimmerman J, Kramer A, McNair D, Malila F . Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med. 2006; 34(5):1297-310. DOI: 10.1097/01.CCM.0000215112.84523.F0. View

17.

Sapru A, Calfee C, Liu K, Kangelaris K, Hansen H, Pawlikowska L . Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med. 2015; 41(3):470-8. PMC: 4500527. DOI: 10.1007/s00134-015-3648-x. View

18.

Prescott H, Calfee C, Thompson B, Angus D, Liu V . Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. Am J Respir Crit Care Med. 2016; 194(2):147-55. PMC: 5003218. DOI: 10.1164/rccm.201512-2544CP. View

19.

Matthay M, Zimmerman G . Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 2005; 33(4):319-27. PMC: 2715340. DOI: 10.1165/rcmb.F305. View

20.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S . Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem. 2011; 44(8-9):601-4. DOI: 10.1016/j.clinbiochem.2010.12.014. View